Home » Stocks » ABCL

AbCellera Biologics, Inc. (ABCL)

Stock Price: $49.08 USD 4.67 (10.52%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $49.00 -0.08 (-0.16%) Jan 19, 7:52 PM
Market Cap 13.03B
Revenue (ttm) 28.45M
Net Income (ttm) 277,000
Shares Out 266.32M
EPS (ttm) 0.00
PE Ratio 47,187.94
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $49.08
Previous Close $44.41
Change ($) 4.67
Change (%) 10.52%
Day's Open 44.94
Day's Range 44.94 - 49.32
Day's Volume 1,252,178
52-Week Range 36.59 - 58.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 hours ago

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni MouseĀ® technology.

CNBC Television - 6 days ago

AbCellera CEO on effectiveness of Covid-19 anitbody treatment

AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments.

GuruFocus - 4 weeks ago

Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Pi...

Other stocks mentioned: FDMT
Business Wire - 4 weeks ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico

Business Wire - 1 month ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

The Motley Fool - 1 month ago

Hot initial public offerings aren't just for technology companies.

Other stocks mentioned: CERT
Barrons - 1 month ago

Four companies increased the size of their deals.

Other stocks mentioned: CERT
Business Wire - 1 month ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.

InvestorPlace - 1 month ago

AbCellera is continuing forward with its IPO plans and has provided new details in a filing with the SEC that investors will want to know. The post ABCL Stock IPO: When Does AbCellera Go Public?

Seeking Alpha - 1 month ago

AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide.

Market Watch - 1 month ago

AbCellera Biologics Inc. ABCL, said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $...

BioSpace - 1 month ago

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19.

Reuters - 1 month ago

Peter Thiel-backed biotech developer AbCellera Biologics Inc, which has partnered with Eli Lilly for its COVID-19 antibody drug, on Friday filed for an initial public offering on the Nasdaq.

NASDAQ - 1 month ago

AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, filed on Friday with the SEC to raise up to $200 million in an initial public offering.

SEC - 1 month ago

AbCellera Biologics, Inc. has filed to go public with an IPO on the NASDAQ.

About ABCL

AbCellera Biologics develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquarter... [Read more...]

Industry
Biotechnology
IPO Date
Dec 11, 2020
CEO
Carl L. G. Hansen
Employees
174
Stock Exchange
NASDAQ
Ticker Symbol
ABCL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ABCL is 51.40, which is an increase of 4.73% from the latest price.

Price Target
$51.40
(4.73% upside)